NCT06072781 2026-03-17
RAMP 301
Verastem, Inc.
Phase 3 Recruiting
Clinical Trials
40 trialsNCT07319429 2026-03-13
FEMUS
Fudan University
Phase 2/3 Recruiting
NCT04931342 2026-03-10
BOUQUET
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT04393285 2026-03-09
Abemaciclib and Letrozole to Treat Endometrial Cancer
GOG Foundation
Phase 2 Active not recruiting
NCT05768139 2026-03-02
PIKALO-1
Eli Lilly and Company
Phase 1/2 Recruiting
NCT03008408 2026-02-11
A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06366347 2026-02-11
ALPINE: Maintenance Letrozole/Abemaciclib
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06394804 2026-02-03
CHAMELEON
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT04095364 2026-01-14
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NRG Oncology
Phase 3 Active not recruiting
NCT06630325 2026-01-07
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT05867251 2025-11-19
Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT01068249 2025-11-18
Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01797523 2025-11-06
A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04111978 2025-09-29
MATAO
Swiss GO Trial Group
Phase 3 Recruiting
NCT04486352 2025-09-04
EndoMAP
Alliance Foundation Trials, LLC.
Phase 1/2 Recruiting
NCT02730429 2025-07-31
Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 2 Completed
NCT04469764 2025-07-29
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT03675893 2025-06-15
RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05247268 2025-04-06
Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer
Fudan University
Phase 2 Recruiting
NCT04421547 2025-03-07
MITO32
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 3 Terminated
NCT05601700 2025-01-27
LEPRE
Ente Ospedaliero Ospedali Galliera
Phase 3 Recruiting
NCT03378297 2024-10-30
IMPACT
Haukeland University Hospital
Phase EARLY_PHASE1 Completed
NCT03936270 2024-02-20
Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer
Latin American Cooperative Oncology Group
Phase 2 Completed
NCT06243185 2024-02-06
Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT05705505 2023-12-12
Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies
Traws Pharma, Inc.
Phase 1/2 Unknown
NCT05712941 2023-11-03
Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer
EQRx International, Inc.
Phase 3 Withdrawn
NCT05203562 2022-07-12
Letrozole as a Prophylaxis From GTN for Complete Mole Patients
Zagazig University
Phase 2/3 Unknown
NCT01999569 2022-04-22
The Role of Estrogen in Luteinizing Hormone Surge and Ovulation
Wake Forest University Health Sciences
Phase 4 Completed
NCT02283658 2020-10-23
Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Mayo Clinic
Phase 2 Completed
NCT00004251 2020-04-06
Letrozole in Treating Women With Recurrent or Metastatic Endometrial Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT03285802 2020-02-05
Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation
Greater Baltimore Medical Center
Phase 2/3 Completed
NCT00414076 2018-11-20
Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00997373 2017-05-30
Letrozole as a Treatment of Endometrial Cancer
University of California, Davis
Phase NA Completed
NCT00171808 2016-11-18
deFEND
Novartis
Phase 2 Completed
NCT00634894 2016-04-20
Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT02482740 2015-06-26
TGOG1005
Buddhist Tzu Chi General Hospital
Phase 2 Unknown
NCT02188550 2015-05-19
Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer
Sinai Hospital of Baltimore
Phase 2 Unknown
NCT00333086 2012-04-19
A Study of Letrozole in the Treatment of Endometrial Cancer
Novartis
Phase 2 Completed
NCT00505661 2012-04-18
Letrozole in Patients With Ovarian Tumors
M.D. Anderson Cancer Center
Phase 2 Terminated